Cipla arm secures marketing rights for cancer drug in US

Cipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2MfBknh
via IFTTT

0 comments:

Post a Comment